Replies to post #70 on Alcobra Ltd fka ADHD

[keekee]

Will attempt to add more today although there are two other great opportunities in my radar

[keekee]

Cantor Fitzgerald maintained its "buy" rating and $16 price target on the stock today following the announcement.

"We have liked the reworked phase III MEASURE study, which has been a key component of our investment thesis," the firm said.

Any issues the FDA has with preclinical information "could be resolved," Cantor added.